View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAlerisLife 将来の成長Future 基準チェック /26主要情報63.8%収益成長率64.04%EPS成長率Healthcare 収益成長18.4%収益成長率68.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日20 Mar 2023今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.Major Estimate Revision • May 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.61 to -US$0.80 per share. Revenue forecast unchanged at US$741.1m. Healthcare industry in the US expected to see average net income growth of 6.6% next year. Consensus price target down from US$5.25 to US$1.50. Share price fell 19% to US$1.25 over the past week.Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Major Estimate Revision • Apr 06Consensus EPS estimates fall by 144%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$792.9m to US$741.8m. Losses expected to increase from US$0.25 per share to US$0.61. Healthcare industry in the US expected to see average net income growth of 3.5% next year. Consensus price target of US$5.25 unchanged from last update. Share price rose 3.3% to US$2.17 over the past week.すべての更新を表示Recent updatesRecent Insider Transactions • Mar 21Chairman & MD recently bought US$29m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly US$1.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Reported Earnings • Nov 04Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 17AlerisLife names new operations chiefAlerisLife (NASDAQ:ALR) announced Monday the appointment of Philip Benjamson as its new senior vice president and chief operating officer, effective Oct. 17, 2022. Benjamson most recently served as VP of Senior Housing Operations for Trinity Health Senior Communities. Previously, he had held the chief operating officer role at Resort Lifestyle Communities and Blake Management Group. "We expect he will have an immediate impact on improving our operations. We are excited to draw on Philip’s expertise as we continue to implement our restructuring plan to improve our operating results," commented AlerisLife President and CEO Jeff Leer. It follows the recent appointment of Heather Pereira as AlerisLife's new Senior Vice President, Chief Financial Officer and Treasurer.Seeking Alpha • Sep 19AlerisLife appoints Heather Pereira as senior VP, CFO and TreasurerAlerisLife (NASDAQ:ALR) appoints Heather Pereira as Senior Vice President, Chief Financial Officer and Treasurer, effective September 19, 2022. Most recently she served as Vice President and Corporate Controller of Acushnet Holdings Corp. since May of 2017. She succeeds Jeff Leer, who, in addition to serving as President and Chief Executive Officer, was also serving as the company’s Chief Financial Officer.Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 22%. Over the next year, revenue is forecast to grow 389%, compared to a 7.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.61 to -US$0.80 per share. Revenue forecast unchanged at US$741.1m. Healthcare industry in the US expected to see average net income growth of 6.6% next year. Consensus price target down from US$5.25 to US$1.50. Share price fell 19% to US$1.25 over the past week.Reported Earnings • May 05First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 59%. Over the next year, revenue is forecast to grow 902%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Major Estimate Revision • Apr 06Consensus EPS estimates fall by 144%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$792.9m to US$741.8m. Losses expected to increase from US$0.25 per share to US$0.61. Healthcare industry in the US expected to see average net income growth of 3.5% next year. Consensus price target of US$5.25 unchanged from last update. Share price rose 3.3% to US$2.17 over the past week.Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Major Estimate Revision • Mar 09Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$772.7m to US$792.9m. Forecast EPS reduced from -US$0.01 to -US$0.25 per share. Healthcare industry in the US expected to see average net income growth of 0.8% next year. Consensus price target down from US$5.50 to US$5.25. Share price rose 4.0% to US$2.57 over the past week.Recent Insider Transactions • Mar 05Insider recently bought US$101k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly US$2.52 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.分析記事 • Mar 01Is AlerisLife (NASDAQ:ALR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 28AlerisLife Still Needs To Execute Despite Wall Street BullishnessCompany misses earnings and sales estimates in Q4. $95 million term-loan increases liquidity and buys the firm time. The valuation and expected profit growth are the real calling cards here. Will they be enough?Price Target Changed • Feb 25Price target decreased to US$5.50Down from US$6.25, the current price target is an average from 2 analysts. New target price is 111% above last closing price of US$2.61. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.015 next year compared to a net loss per share of US$0.95 last year.Reported Earnings • Feb 25Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 28%. Over the next year, revenue is forecast to grow 329%, compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 29Five Star: A Professional Opportunity For The Retail InvestorFive Star is trading well below intrinsic value with an upside of over 100%. The company should be more profitable over time as they focus on their more profitable revenue streams, assisted living and rehab/wellness clinics. Five Star has possible tailwinds which should drive revenue/ profitability higher over the long term. Professional investors are not able to buy enough shares of the stock due to a low float, which creates an opportunity for individual investors.Seeking Alpha • Sep 22Five Star Senior Living: The $3.80 Level Most Likely The BottomShares have now lost over half of their value since February of this year. We though are beginning to see green shoots in the financials. Five Star remains profitable from a cash standpoint. We expect fiscal 2022 to report positive net profit.Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$911.4m to US$960.0m. Forecast EPS reduced from -US$0.18 to -US$0.59 per share. Healthcare industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$7.50 to US$6.25. Share price fell 18% to US$4.28 over the past week.Price Target Changed • Aug 09Price target decreased to US$6.75Down from US$7.75, the current price target is an average from 2 analysts. New target price is 57% above last closing price of US$4.30. Stock is down 11% over the past year.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$4.63, the stock trades at a trailing P/E ratio of 11.3x. Average forward P/E is 20x in the Healthcare industry in the US. Total loss to shareholders of 59% over the past three years.Seeking Alpha • Jul 26Five Star Senior Living: Buy Your Winter Coats In SummerThis Senior Home provider is still very much profitable from a cash flow standpoint, despite falling revenues. The company continues to pivot its model towards more its more core-based offerings. We see "locked-up" value in its assets. We see a mean reversion with respect to valuation before long.Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$5.97, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 22x in the Healthcare industry in the US. Total loss to shareholders of 50% over the past three years.分析記事 • May 09Is Now The Time To Look At Buying Five Star Senior Living Inc. (NASDAQ:FVE)?While Five Star Senior Living Inc. ( NASDAQ:FVE ) might not be the most widely known stock at the moment, it saw a...Reported Earnings • May 06First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.分析記事 • Apr 12Five Star Senior Living (NASDAQ:FVE) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 14Analysts Are Optimistic We'll See A Profit From Five Star Senior Living Inc. (NASDAQ:FVE)Five Star Senior Living Inc. ( NASDAQ:FVE ) is possibly approaching a major achievement in its business, so we would...Is New 90 Day High Low • Mar 04New 90-day low: US$6.19The company is down 8.0% from its price of US$6.74 on 03 December 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is flat over the same period.Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (US$17k worth at the time). Ellen is the only executive to leave the company over the last 12 months.Reported Earnings • Feb 25Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$1.17b (up 6.0% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.4%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Over the next year, revenue is forecast to grow 2.8%, compared to a 10% growth forecast for the Healthcare industry in the US.分析記事 • Feb 16What Is The Ownership Structure Like For Five Star Senior Living Inc. (NASDAQ:FVE)?A look at the shareholders of Five Star Senior Living Inc. ( NASDAQ:FVE ) can tell us which group is most powerful...Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$8.66, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32x. This compares to an average P/E of 29x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 36%.Is New 90 Day High Low • Feb 06New 90-day high: US$8.66The company is up 91% from its price of US$4.54 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 2.0% over the same period.分析記事 • Jan 29Five Star Senior Living's (NASDAQ:FVE) Shareholders Are Down 71% On Their SharesFive Star Senior Living Inc. ( NASDAQ:FVE ) shareholders will doubtless be very grateful to see the share price up 55...分析記事 • Jan 12Is Five Star Senior Living (NASDAQ:FVE) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Dec 25Should You Think About Buying Five Star Senior Living Inc. (NASDAQ:FVE) Now?Five Star Senior Living Inc. ( NASDAQ:FVE ), might not be a large cap stock, but it led the NASDAQCM gainers with a...Is New 90 Day High Low • Dec 11New 90-day high: US$7.44The company is up 42% from its price of US$5.24 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 17% over the same period.分析記事 • Dec 07Has Five Star Senior Living Inc.'s (NASDAQ:FVE) Impressive Stock Performance Got Anything to Do With Its Fundamentals?Five Star Senior Living (NASDAQ:FVE) has had a great run on the share market with its stock up by a significant 57...Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 17% share price gain to US$7.16, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27x. This compares to an average P/E of 23x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 52%.Valuation Update With 7 Day Price Move • Nov 28Market bids up stock over the past weekAfter last week's 17% share price gain to US$6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 24x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 62%.Is New 90 Day High Low • Nov 25New 90-day high: US$5.68The company is up 9.0% from its price of US$5.19 on 26 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Healthcare industry, which is also up 9.0% over the same period.分析記事 • Nov 19Are Five Star Senior Living's (NASDAQ:FVE) Statutory Earnings A Good Guide To Its Underlying Profitability?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 03New 90-day low: US$4.49The company is down 4.0% from its price of US$4.66 on 04 August 2020. The American market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.業績と収益の成長予測NasdaqCM:ALR - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2023789-15N/A-4112/31/2022713-34N/A-4719/30/2022160-38-69-54N/A6/30/2022161-39-78-64N/A3/31/2022168-43-81-68N/A12/31/2021180-30-17-8N/A9/30/2021193-16-18-9N/A6/30/2021205-22229N/A3/31/2021213136773N/A12/31/2020222-84651N/A9/30/202043762246N/A6/30/2020656-5-631N/A3/31/2020880-4-54-7N/A12/31/20191,101-20-62-4N/A9/30/20191,114-60-66-16N/A6/30/20191,116-74-75-25N/A3/31/20191,112-99-85-34N/A12/31/20181,110-74-103-54N/A9/30/20181,112-51-88-35N/A6/30/20181,119-36-75-19N/A3/31/20181,128-22-65-3N/A12/31/20171,136-21-5417N/A9/30/20171,138-26-6010N/A6/30/20171,137-25-74-8N/A3/31/20171,139-26-71-11N/A12/31/20161,136-22-79-23N/A9/30/20161,135-22-60-3N/A6/30/20161,135-43N/A12N/A3/31/20161,130-38N/A18N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ALR今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: ALR今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: ALR今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: ALRの収益 ( 68.9% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: ALRの収益 ( 68.9% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ALRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/03/21 11:46終値2023/03/17 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AlerisLife Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Bryan MaherB. Riley Securities, Inc.Joseph FranceCantor Fitzgerald & Co.Peter MartinCitizens JMP Securities, LLC7 その他のアナリストを表示
Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.
Major Estimate Revision • May 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.61 to -US$0.80 per share. Revenue forecast unchanged at US$741.1m. Healthcare industry in the US expected to see average net income growth of 6.6% next year. Consensus price target down from US$5.25 to US$1.50. Share price fell 19% to US$1.25 over the past week.
Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Major Estimate Revision • Apr 06Consensus EPS estimates fall by 144%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$792.9m to US$741.8m. Losses expected to increase from US$0.25 per share to US$0.61. Healthcare industry in the US expected to see average net income growth of 3.5% next year. Consensus price target of US$5.25 unchanged from last update. Share price rose 3.3% to US$2.17 over the past week.
Recent Insider Transactions • Mar 21Chairman & MD recently bought US$29m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly US$1.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Nov 16Price target decreased to US$1.50Down from US$2.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of US$0.83. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$0.95 last year.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Reported Earnings • Nov 04Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 17AlerisLife names new operations chiefAlerisLife (NASDAQ:ALR) announced Monday the appointment of Philip Benjamson as its new senior vice president and chief operating officer, effective Oct. 17, 2022. Benjamson most recently served as VP of Senior Housing Operations for Trinity Health Senior Communities. Previously, he had held the chief operating officer role at Resort Lifestyle Communities and Blake Management Group. "We expect he will have an immediate impact on improving our operations. We are excited to draw on Philip’s expertise as we continue to implement our restructuring plan to improve our operating results," commented AlerisLife President and CEO Jeff Leer. It follows the recent appointment of Heather Pereira as AlerisLife's new Senior Vice President, Chief Financial Officer and Treasurer.
Seeking Alpha • Sep 19AlerisLife appoints Heather Pereira as senior VP, CFO and TreasurerAlerisLife (NASDAQ:ALR) appoints Heather Pereira as Senior Vice President, Chief Financial Officer and Treasurer, effective September 19, 2022. Most recently she served as Vice President and Corporate Controller of Acushnet Holdings Corp. since May of 2017. She succeeds Jeff Leer, who, in addition to serving as President and Chief Executive Officer, was also serving as the company’s Chief Financial Officer.
Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.
Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 22%. Over the next year, revenue is forecast to grow 389%, compared to a 7.9% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.61 to -US$0.80 per share. Revenue forecast unchanged at US$741.1m. Healthcare industry in the US expected to see average net income growth of 6.6% next year. Consensus price target down from US$5.25 to US$1.50. Share price fell 19% to US$1.25 over the past week.
Reported Earnings • May 05First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 59%. Over the next year, revenue is forecast to grow 902%, compared to a 9.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Major Estimate Revision • Apr 06Consensus EPS estimates fall by 144%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$792.9m to US$741.8m. Losses expected to increase from US$0.25 per share to US$0.61. Healthcare industry in the US expected to see average net income growth of 3.5% next year. Consensus price target of US$5.25 unchanged from last update. Share price rose 3.3% to US$2.17 over the past week.
Breakeven Date Change • Apr 06Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Major Estimate Revision • Mar 09Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$772.7m to US$792.9m. Forecast EPS reduced from -US$0.01 to -US$0.25 per share. Healthcare industry in the US expected to see average net income growth of 0.8% next year. Consensus price target down from US$5.50 to US$5.25. Share price rose 4.0% to US$2.57 over the past week.
Recent Insider Transactions • Mar 05Insider recently bought US$101k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly US$2.52 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
分析記事 • Mar 01Is AlerisLife (NASDAQ:ALR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Feb 28AlerisLife Still Needs To Execute Despite Wall Street BullishnessCompany misses earnings and sales estimates in Q4. $95 million term-loan increases liquidity and buys the firm time. The valuation and expected profit growth are the real calling cards here. Will they be enough?
Price Target Changed • Feb 25Price target decreased to US$5.50Down from US$6.25, the current price target is an average from 2 analysts. New target price is 111% above last closing price of US$2.61. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.015 next year compared to a net loss per share of US$0.95 last year.
Reported Earnings • Feb 25Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 28%. Over the next year, revenue is forecast to grow 329%, compared to a 9.8% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 29Five Star: A Professional Opportunity For The Retail InvestorFive Star is trading well below intrinsic value with an upside of over 100%. The company should be more profitable over time as they focus on their more profitable revenue streams, assisted living and rehab/wellness clinics. Five Star has possible tailwinds which should drive revenue/ profitability higher over the long term. Professional investors are not able to buy enough shares of the stock due to a low float, which creates an opportunity for individual investors.
Seeking Alpha • Sep 22Five Star Senior Living: The $3.80 Level Most Likely The BottomShares have now lost over half of their value since February of this year. We though are beginning to see green shoots in the financials. Five Star remains profitable from a cash standpoint. We expect fiscal 2022 to report positive net profit.
Major Estimate Revision • Aug 12Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$911.4m to US$960.0m. Forecast EPS reduced from -US$0.18 to -US$0.59 per share. Healthcare industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$7.50 to US$6.25. Share price fell 18% to US$4.28 over the past week.
Price Target Changed • Aug 09Price target decreased to US$6.75Down from US$7.75, the current price target is an average from 2 analysts. New target price is 57% above last closing price of US$4.30. Stock is down 11% over the past year.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$4.63, the stock trades at a trailing P/E ratio of 11.3x. Average forward P/E is 20x in the Healthcare industry in the US. Total loss to shareholders of 59% over the past three years.
Seeking Alpha • Jul 26Five Star Senior Living: Buy Your Winter Coats In SummerThis Senior Home provider is still very much profitable from a cash flow standpoint, despite falling revenues. The company continues to pivot its model towards more its more core-based offerings. We see "locked-up" value in its assets. We see a mean reversion with respect to valuation before long.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$5.97, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 22x in the Healthcare industry in the US. Total loss to shareholders of 50% over the past three years.
分析記事 • May 09Is Now The Time To Look At Buying Five Star Senior Living Inc. (NASDAQ:FVE)?While Five Star Senior Living Inc. ( NASDAQ:FVE ) might not be the most widely known stock at the moment, it saw a...
Reported Earnings • May 06First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
分析記事 • Apr 12Five Star Senior Living (NASDAQ:FVE) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Mar 14Analysts Are Optimistic We'll See A Profit From Five Star Senior Living Inc. (NASDAQ:FVE)Five Star Senior Living Inc. ( NASDAQ:FVE ) is possibly approaching a major achievement in its business, so we would...
Is New 90 Day High Low • Mar 04New 90-day low: US$6.19The company is down 8.0% from its price of US$6.74 on 03 December 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is flat over the same period.
Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (US$17k worth at the time). Ellen is the only executive to leave the company over the last 12 months.
Reported Earnings • Feb 25Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$1.17b (up 6.0% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Feb 25Revenue and earnings miss expectationsRevenue missed analyst estimates by 0.4%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Over the next year, revenue is forecast to grow 2.8%, compared to a 10% growth forecast for the Healthcare industry in the US.
分析記事 • Feb 16What Is The Ownership Structure Like For Five Star Senior Living Inc. (NASDAQ:FVE)?A look at the shareholders of Five Star Senior Living Inc. ( NASDAQ:FVE ) can tell us which group is most powerful...
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$8.66, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32x. This compares to an average P/E of 29x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 36%.
Is New 90 Day High Low • Feb 06New 90-day high: US$8.66The company is up 91% from its price of US$4.54 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 2.0% over the same period.
分析記事 • Jan 29Five Star Senior Living's (NASDAQ:FVE) Shareholders Are Down 71% On Their SharesFive Star Senior Living Inc. ( NASDAQ:FVE ) shareholders will doubtless be very grateful to see the share price up 55...
分析記事 • Jan 12Is Five Star Senior Living (NASDAQ:FVE) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Dec 25Should You Think About Buying Five Star Senior Living Inc. (NASDAQ:FVE) Now?Five Star Senior Living Inc. ( NASDAQ:FVE ), might not be a large cap stock, but it led the NASDAQCM gainers with a...
Is New 90 Day High Low • Dec 11New 90-day high: US$7.44The company is up 42% from its price of US$5.24 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 17% over the same period.
分析記事 • Dec 07Has Five Star Senior Living Inc.'s (NASDAQ:FVE) Impressive Stock Performance Got Anything to Do With Its Fundamentals?Five Star Senior Living (NASDAQ:FVE) has had a great run on the share market with its stock up by a significant 57...
Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 17% share price gain to US$7.16, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27x. This compares to an average P/E of 23x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 52%.
Valuation Update With 7 Day Price Move • Nov 28Market bids up stock over the past weekAfter last week's 17% share price gain to US$6.10, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 24x in the Healthcare industry in the US. Total return to shareholders over the past three years is a loss of 62%.
Is New 90 Day High Low • Nov 25New 90-day high: US$5.68The company is up 9.0% from its price of US$5.19 on 26 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Healthcare industry, which is also up 9.0% over the same period.
分析記事 • Nov 19Are Five Star Senior Living's (NASDAQ:FVE) Statutory Earnings A Good Guide To Its Underlying Profitability?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 03New 90-day low: US$4.49The company is down 4.0% from its price of US$4.66 on 04 August 2020. The American market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period.